Gene Therapy: Page 22
-
Getty / Edited by BioPharma Dive
Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline
The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research.
By Kristin Jensen • March 3, 2021 -
Bluebird reveals new details on cancer cases in gene therapy trial
Executives shared an update on the biotech's investigation of the two cases at an investor conference, rather than via a statement or regulatory filing.
By Ned Pagliarulo • Feb. 26, 2021 -
Explore the Trendline➔
Getty Images
TrendlineGene Therapy
Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges.
By BioPharma Dive staff -
Former AveXis executives launch gene therapy startup with uncommon targets
Sean Nolan and Joe Nolan, former leaders at the Zolgensma developer, are behind Jaguar Gene Therapy, which plans to research treatments for a rare metabolic disease as well as genetically linked autism and diabetes.
By Ned Pagliarulo • Feb. 25, 2021 -
Beam, capitalizing on stock surge, buys gene therapy tools developer for $120M
Guide Therapeutics, the company Beam acquired, is working on ways to more efficiently deliver gene editing therapies into the body.
By Ned Pagliarulo • Feb. 23, 2021 -
Gates Foundation backs Novartis' search for a sickle cell cure
An initial grant will support a research team at Novartis' R&D labs whose sole focus will be to develop a single-administration gene therapy for sickle cell disease.
By Jacob Bell • Feb. 17, 2021 -
Getty / Edited by BioPharma Dive
Bluebird stops studies of sickle cell gene therapy after new cancer cases
The biotech is also suspending sales of its related treatment Zynteglo following a leukemia diagnosis in a clinical trial volunteer and a case of a cancer-like bone marrow disease in another.
By Ben Fidler , Ned Pagliarulo • Updated Feb. 16, 2021 -
Danielle Ternes/BioPharma Dive
A gene therapy pipeline takes shape for a cluster of rare diseases
Lysosomal storage disorders, diseases of cellular metabolism gone wrong, are the focus of a fast-expanding lineup of experimental genetic medicines, a research boom that recalls biotech's roots.
By Ned Pagliarulo • Feb. 12, 2021 -
Getty / Edited by BioPharma Dive
A new startup gets Takeda's backing to take complex genetic medicines 'off the shelf'
Ensoma debuts with a lucrative alliance with the Japanese pharma and an unusual way to deliver genetic medicines into the body.
By Ben Fidler • Feb. 11, 2021 -
Getty / Edited by BioPharma Dive
AbbVie exploring how CRISPR gene editing can improve cell therapies
Using technology from Caribou Biosciences, AbbVie hopes to engineer "off-the-shelf" CAR-T cells that can better withstand attacks from the immune system.
By Jacob Bell • Feb. 10, 2021 -
Courtesy of Editas Medicine
Editas names new CEO in latest executive shakeup
James Mullen, chair of Editas' board and a former Biogen CEO, will replace Cynthia Collins in a critical year for the gene editing biotech.
By Ned Pagliarulo • Feb. 8, 2021 -
Permission granted by Bristol-Myers Squibb
Bristol Myers finally wins FDA approval for cancer cell therapy
Delays tied to factory inspections had pushed an FDA decision on Breyanzi past a key deadline, allowing Bristol Myers to avoid paying billions of dollars in payouts to investors.
By Ned Pagliarulo , Ben Fidler • Feb. 5, 2021 -
With $588M IPO, Sana leads wave of new biotechs going public
Nine other drug developers are set to price initial public offerings this week, extending a record run of financing activity from last year. Sana's is one of the largest in recent history.
By Ben Fidler • Feb. 3, 2021 -
Neurocine ends partnership with Voyager for Parkinson's gene therapy
The loss of Neurocrine as a collaborator is another blow to Voyager after the FDA placed a clinical hold on the experimental treatment.
By Kristin Jensen • Feb. 3, 2021 -
Danielle Ternes/BioPharma Dive
Gene therapy for hemophilia: So close, yet so far away
Significant setbacks for pace-setting programs from BioMarin and UniQure have renewed questions about gene therapy’s promise, and its safety.
By Ben Fidler • Jan. 28, 2021 -
How 2 scientific pioneers teamed up to run AskBio, Bayer's new gene therapy division
Katherine High and Jude Samulski, two well-known gene therapy researchers, were longtime collaborators and competitors. Now they're colleagues at one of the world's largest drugmakers.
By Sarah de Crescenzo • Jan. 21, 2021 -
Courtesy of BioMarin Pharmaceutical
BioMarin tries to get hemophilia gene therapy back on track with positive data
Full one-year results from a Phase 3 study show the therapy, known as Roctavian, sharply reduced bleeds and use of blood-clotting treatments.
By Ned Pagliarulo • Jan. 11, 2021 -
Yujin Kim/BioPharma Dive
5 questions facing gene therapy in 2021
Gene therapy developers will need to address a series of setbacks that have shaded optimism in the sector's fast growth. Dealmaking, however, appears to be continuing apace.
By Ned Pagliarulo • Jan. 8, 2021 -
Getty / Edited by BioPharma Dive
Sarepta gene therapy misses goal in key muscular dystrophy study
Company executives, however, blamed "improbably bad luck" for study enrollment that resulted in more older patients with milder disease receiving placebo, and pledged to press on.
By Jonathan Gardner • Jan. 7, 2021 -
Pfizer beats Sarepta to start of first late-stage Duchenne gene therapy trial
Sarepta, though, may try to seek accelerated approval using Phase 2 data that's due imminently, along with results from another, smaller trial.
By Jonathan Gardner • Jan. 7, 2021 -
Getty / Edited by BioPharma Dive
Biogen pushes further into eye gene therapy with new deal
Partnering with German biotech ViGeneron bolsters Biogen's pipeline of drugs for eye diseases, which includes assets acquired through its buyout of Nightstar Therapeutics.
By Kristin Jensen • Jan. 6, 2021 -
Getty / Edited by BioPharma Dive
Cancer case puts UniQure's hemophilia gene therapy on hold, raising alarms
The FDA halted the AMT-061 program, which could be the first approved gene therapy for hemophilia B, because a patient who received the treatment appears to have developed liver cancer.
By Jacob Bell • Dec. 21, 2020 -
Courtesy of Eli Lilly
Lilly pays $880M for Prevail, pushing further into genetic medicine
The acquisition marks a significant bet by Lilly on gene therapy's potential to address tough-to-treat neurological disorders like Parkinson's disease.
By Jonathan Gardner • Dec. 15, 2020 -
UniQure offers a closer look at the leading hemophilia B gene therapy
Doctors on Tuesday got a more detailed idea of how the therapy works and who might be eligible to take it, as late-stage results were presented at ASH.
By Jacob Bell • Dec. 8, 2020 -
Bayer strikes a deal with Atara, wading deeper into cell therapy
A pact for two Atara programs continues the German pharma's efforts to use dealmaking to build a gene and cell therapy division.
By Ben Fidler • Dec. 7, 2020 -
Jonathan Gardner/BioPharma Dive
4 storylines to track at the year's biggest meeting on blood diseases
A closely watched gene editing therapy, a slate of new multiple myeloma drugs and much more are set to highlight the American Society of Hematology conference this weekend.
By Ben Fidler , Ned Pagliarulo , Jacob Bell • Dec. 3, 2020
Previous
